These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19413736)

  • 21. Designing a data and safety monitoring plan.
    Slimmer L; Andersen B
    West J Nurs Res; 2004 Nov; 26(7):797-803. PubMed ID: 15466615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The many moral responsibilities of independent data-monitoring committees.
    Braillon A
    Am J Bioeth; 2011 Mar; 11(3):16-7. PubMed ID: 21400378
    [No Abstract]   [Full Text] [Related]  

  • 23. The impact of escalating regulatory requirements on the conduct of clinical research.
    Gordon BG; Kessinger A; Mann SL; Prentice ED
    Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-based interventions for neurologic conditions: ethical challenges for early human trials.
    Mathews DJ; Sugarman J; Bok H; Blass DM; Coyle JT; Duggan P; Finkel J; Greely HT; Hillis A; Hoke A; Johnson R; Johnston M; Kahn J; Kerr D; Kurtzberg J; Liao SM; McDonald JW; McKhann G; Nelson KB; Rao M; Regenberg A; Siegel AW; Smith K; Solter D; Song H; Vescovi A; Young W; Gearhart JD; Faden R
    Neurology; 2008 Jul; 71(4):288-93. PubMed ID: 18463365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety boards must report their conclusions to IRBs.
    Maloney DM
    Hum Res Rep; 1999 Oct; 14(10):3. PubMed ID: 11658061
    [No Abstract]   [Full Text] [Related]  

  • 27. Board games.
    Nature; 2007 Aug; 448(7153):511-2. PubMed ID: 17671461
    [No Abstract]   [Full Text] [Related]  

  • 28. Committee for Medicinal Products for Human Use (CHMP) guideline on Data Monitoring Committees.
    ; ;
    Stat Med; 2006 May; 25(10):1639-45. PubMed ID: 16639775
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety panel backs principle of gene-therapy trials.
    Check E
    Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
    [No Abstract]   [Full Text] [Related]  

  • 30. Data safety and monitoring boards.
    Slutsky AS; Lavery JV
    N Engl J Med; 2004 Mar; 350(11):1143-7. PubMed ID: 15014189
    [No Abstract]   [Full Text] [Related]  

  • 31. Notes from the director of the National Heart, Lung, and Blood Institute: shaping the future of research: the NHLBI strategic plan.
    Nabel EG
    Circulation; 2007 Nov; 116(21):2479-80. PubMed ID: 18025405
    [No Abstract]   [Full Text] [Related]  

  • 32. Standard 3: data monitoring committees.
    Ellenberg S; Fernandes RM; Saloojee H; Bassler D; Askie L; Vandermeer B; Offringa M; Van der Tweel I; Altman DG; van der Lee JH;
    Pediatrics; 2012 Jun; 129 Suppl 3():S132-7. PubMed ID: 22661759
    [No Abstract]   [Full Text] [Related]  

  • 33. Role of the data safety and monitoring board in an international trial.
    NIMH Collaborative HIV/STD Prevention Trial
    AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thought exercises on accountability and performance measures at the National Heart, Lung, and Blood Institute (NHLBI): an invited commentary for circulation research.
    Lauer MS
    Circ Res; 2011 Feb; 108(4):405-9. PubMed ID: 21335430
    [No Abstract]   [Full Text] [Related]  

  • 35. Data monitoring (and safety) committees--what are they and why do we need them? Primary Care Alliance for Clinical Trials (PACT) Network.
    Pirotta M; Chondros P;
    Aust Fam Physician; 2004 Nov; 33(11):950-1, 956. PubMed ID: 15584339
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of the unblinded sponsor statistician.
    Snapinn S; Cook T; Shapiro D; Snavely D
    Stat Med; 2004 May; 23(10):1531-3. PubMed ID: 15122733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Institutional review boards (IRBs) and working with adverse event reports.
    Maloney DM
    Hum Res Rep; 2005 Dec; 20(12):1-3. PubMed ID: 16607708
    [No Abstract]   [Full Text] [Related]  

  • 39. Continued concern: human subject protection, the institutional review board, and continuing review.
    Hoffman S
    Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
    [No Abstract]   [Full Text] [Related]  

  • 40. An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627.
    Stat Med; 2007 Jan; 26(1):230-3; author reply 234-5. PubMed ID: 16900566
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.